Aurobindo Pharma arm terminates agreement with Hilleman Labs Singapore for pentavalent vaccine
Hyderabad: Aurobindo Pharma has announced that Auro Vaccines Private Limited, a wholly owned step-down subsidiary of the Company, has terminated the License Agreement entered in September with Hilleman Laboratories Singapore Pte, Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Pentavalent vaccine provides protection to a child from 5 life-threatening diseases – Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib.
Read also: Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine
"Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. It may also be noted that this termination of Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures," Aurobindo noted in a BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.